Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of JNJ-64417184 in Renal Impairment
NCT04426357Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JNJ-64417184 in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Analyte Concentration at 216 hours, Area under the Plasma Analyte Concentration Time Curve from Time 0 to Time of the Last Measurable Concentration at 216 hours and 1 more. Started Jul 2020; status: terminated.
02
Drugs
JNJ-64417184
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04426357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04426357.